Cheyne-Stokes respiration pathophysiology

Cheyne-Stokes respiration Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cheyne-Stokes respiration from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cheyne-Stokes respiration pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cheyne-Stokes respiration pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cheyne-Stokes respiration pathophysiology

CDC on Cheyne-Stokes respiration pathophysiology

Cheyne-Stokes respiration pathophysiology in the news

Blogs on Cheyne-Stokes respiration pathophysiology

Directions to Hospitals Treating Cheyne-Stokes respiration

Risk calculators and risk factors for Cheyne-Stokes respiration pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview

[edit | edit source]

## Pathophysiology

[edit | edit source]

### Pathophysiology in Patients with CHF

[edit | edit source]

The exact mechanisms responsible for the development of CSR are unknown. Among the more important factors are hyperventilation, and a prolonged circulatory time.

* Hyperventilation and resultant hypocapnia, is thought to occur in patients with CHF due to stimulation of pulmonary mechanoreceptors by interstitial edema.

* Patients with CHF and CSR have been found to have lower awake and sleep PaCO2 levels, and increased minute ventilation as compared to patients with CHF without CSR.
* In addition, the apnea threshold (the PaCO2 below which apnea occurs) also seems to be increased in patients with CHF and CSR.
* Furthermore, hypoxemia shifts the ventilatory response curve for CO2 up and to the left (higher ventilation at any given CO2). This reduces the stability of the ventilatory control system.
* Thus, hyperventilation reduces the PaCO2 below the apnea threshold, and as PaCO2 rises, an exaggerated ventilatory response causes the PaCO2 to fall below the apnea threshold, and a vicious cycle ensued.
* Prolonged circulatory time, as a marker of severity of CHF, is directly correlated to the duration of sleep spent in CSR, as well as the cycle length of each episode.

* This is due to an increase in the oscillation around a set point PaO2 and PaCO2. As circulatory time increases, the PaO2 and PaOC2 become more out of phase with the respiratory pattern set by the ventilatory control centers (carotid body and medulla).
* It also seems that patients with CHF have less ability to buffer changes in PaCO2, i.e. the system is underdamped. This results from the fact that CHF causes a decrease in FRC, which reduces total body stores of CO2 and O2. It has been shown that, as total body stores of CO2 decrease, the body is not able to buffer the transient changes in PaCO2 as well.

### Pathophysiology in Patients with Stroke

[edit | edit source]

There is a lot less data on the mechanisms of CSR in patients with CNS disease, than in patients with CHF. Some potential mechanisms include a delay in afferent, efferent neural transmission, delays in central processing of afferent signals, slowed brain blood flow, and altered chemoresponsiveness with a heightened ventilatory responsiveness.

## References

[edit | edit source]

Template:WH Template:WS